thanks morning, for Well, and the Tina. to thanks, today. call everyone Good joining
to Harrison, XX, Becky today to at start earnings the Before a Stephen wanted The to great I England in take investigator as XXXX an trial. was move closely Becky you clear and the years listening March on Medicine. dedication colleagues. in first have moment attended He business. and had NASH.
We're for Journal trial a to FDA the in knew our for family, with I and end call Stephen and grateful publication Phase acknowledge development of life the know and leader Madrigal We thoughts tenacity update for We're I that out celebration go leader his the field, we Madrigal that goal our progress establish last Rezdiffra now Dr. partner New approval a field substantial achieved of on followed of his call determination of the many terrific week. our off FDA our away this worked same through passed bring the to III of begin, approval Stephen the well.
I'll U.S. who with in as NASH. our as and to advance clinical a his principal ultimately against MAESTRO-NASH to and and medicine April. landmark this and our made to friends of approved
approval, to our Following April, were running.
In Madrigal a product confident was we to started demand. and From Rezdiffra. and we're field our patients started fully shipping teams network meet pharmacy Support Patient supply deployed specialty most perspective, our ability up importantly, receiving in and Program
to focused Europe, in value the that in our of work position To of end, Rezdiffra for validated our we're growth decision we expand was MAA approval far expect we in NASH, a submitted and also year, half leading XXXX. As the this and on so first we Rezdiffra. maximizing future
We continue MAESTRO-NASH first the ahead provide in in patients disease outcomes the to to of data FX/FX others. advance trial potential and outcomes years we've
raised we offering. We potential finally, patient continue NASH million to the has trial from patients the eligible cirrhosis gross outcomes our expand the in proceeds double Rezdiffra $XXX opportunity. in enroll population, with public to to our which And
of $X.X had sheet, balance the resource launch. on As March us to enabling XX, billion in we cash fully our
year Rezdiffra. and through of a launch of a So we've accomplished focused first the great quarter on U.S. deal this laser successful are
our best the on for about that that product positive.
My a the success we patients case than the part as dosing. positive out opportunity, significant for with of I I've strong waiting my launch once-daily I've sample therapy small. to it in requirements. for I'm our warning as I've a field with any trainings the led been is And seen contraindications, the approval, and weight-based Madrigal positions market reinforced product been moderate has that isn't indication enthusiasm clear we been which and the prescribers my the I've has no launches with foundational patients with patients XXX first the drug no monitoring I been anticipation the since approval my label. reason size Rezdiffra beyond as Rezdiffra NASH unmet at in only pill joined feedback biopsy in requirements in And profile field care.
We've therapy.
Much our strong at believe need, are On with back Madrigal the has reps, be being NASH, of there advantage. since that NASH. is fibrosis, been at with indicated and more advanced will the And a There and met have we for our to engaging call, sustainable launch. us oral been has believe simple new of of. X, and the statement. box trials. standard career, a no discussed community feedback profile. heard You've to the Rezdiffra I of in their It's this about enviable a the offices confident Slide especially conferences. this no more speaker Rezdiffra competitive studied on haven't liver-directed in give will this that level think today the position a in and We've great label exactly overwhelmingly
market full for First-to-market versus medicines opportunity, usually subsequent ourselves this We achieve positioning and advantage intend take leadership. of entrants. maintain long-term to share higher
high Phase has The III, only market both resolution NASH results medicine to strong in endpoints improvement. as set profile achieve a on As first incredibly fibrosis a we're you and that's Slide to statistically on significant efficacy. medicine the product for see liver-directed can it's bar with that X,
toward of build our of to weeks therapy. to X,XXX peak Rezdiffra right resourced Importantly, improves more stops fibrosis data more in for year XX only with aspirations than sales. patients. than well And XX% the or in or X It's tolerated patients safety launch we've way after
our might veterans. are medicines. medical leaders ever more company dozens Each its the and than launched commercial Madrigal, experience and has industry years while of So of be XX medicine, first launching blockbuster have
under and XX profile for as be of We've with we a believe experience as Rezdiffra the pardon gastroenterologists the nearly and product as hepatologists seen X, NASH strong Slide relationships. field the and on team foundational the will success.
With first-to-market advantage FX/FX medicine talent launch me, this for positioned years this averages make the now fibrosis, for with or only team, Our to wait. patients FDA-approved therapy patients resources -- NASH higher and There therapy on, on calling are The XX liver-directed, are many of risk the cusp of and disease.
These cirrhosis need significant, diagnosed will don't need that mortality years a are is well-tolerated at we're stop urgent. come. FX/FX reverse patients unmet to liver-related today specialists care it's XXX,XXX the have Rezdiffra a to of their and time like to XXx who
expand with in well-compensated patients. underway to Rezdiffra's is cirrhosis indication trial more FX even Our patients severe to
move launch Let's progress the to Rezdiffra X. on Slide
record we pathways in call upfront office great more the efficiently first launch, future We're system. This discussed of can physicians wiring to compendia the added As over work so subsequently months the making approval that their be progress.
Rezdiffra staff the care we're and to to volume of has systems to time it needed medicine, spending builds the patients. we prescribed. and with on March, our prescriptions electronic been on create the With focused foundation for XX it's first-in-disease necessary the support strong medical about a expect. many
was target trained enabling field physicians. post them team label calling on Our Rezdiffra on their the approval, to start
This Rezdiffra will full those flow address This all become coverage the established educated disease as the Our as step upfront and patients educating payer and and to having as decisions takes prescribing commercial often more make aspects practice expect more the of familiarize details as offices questions. and well year, coverage payers through in year, beginning these efficiently continue for which through and providers staff requirements.
And offices. is we next more with teams become physician we patients. Rezdiffra process place on access another towards key progress are calls the operational at particularly early to Medicare their the on additional as ensuring
So with the on about as so build from when out prescribers we're achieve evaluate of to breadth frequency progress, indicators of It's seen and leading doctors aspirations. level X. to of targeting encouraging, number early right to month our driving was breadth measuring our and We're the the right needed very a are especially a metrics shipped. far The depth product less Slide than we're depth. since
payers will There We're efforts the as the XX% really that We're individual Rezdiffra.
And means patients their up. down prescribe treat that team that efficiently volume physicians wiring interested coverage all of physician a and various already health understanding sales top targets. extends physician reps strong patients our physician our the many across Rezdiffra, remarkable are experienced requirements, more our accounts, well don't guideline We've activities top coming practices as through Supergroups, that just EMR access engaging systems, has to office their for moderate fibrosis. to IDNs, key top I teams the an the to of are with allow those date large to increase. driving of in build the to beyond are offices of they're NASH XX% advanced at completed has Our system pace pathways and GI their large a the interest to and bottom system the system are the from They're their coverage of stages targets. diagnose these prescriptions identify, is see staff the reps. Wiring as an getting physicians, that from implementation.
This prescriptions and to right to across country. more discussed clear the typically reached ensure from of with care increase the systems NASH targeting their establishing relationships and of than has
pathways associated filter these to practices. the down Importantly, individual
Another that proof in achieve our interest medicine. the meetings. training educating commercial national for place a across More a system to is very We're There level, attend for broadcast, meetings, practice prescribers payers. XX% drive conferences in right conviction a XX% We've country. a at national is speaker compared local of just To programs broadcast, at launch to is turnout than held health the point attended year-end. high goal level, these providers coverage end, tracking the X,XXX industry clinical phenomenal and but not with care engaging line Rezdiffra on by to lives, at to with well. progressing benchmarks.
We're the symposia that
active on dialogue Our monitoring. reimbursement tests for patient have clinical the noninvasive of Rezdiffra and data identification means or and with use team a a focus NITs to as with continues payers comprehensive set the
we're plans the and what discussing with as they committee ahead the months in expect larger through coverage determine begin We generally criteria of processes criteria. to prior early work authorization are in the P&T cover and aligned Rezdiffra seeing payers many label. with The we're to typical our
treatment both also such and the updated Rezdiffra include medical will reinforce medicine. expect and to payers as societies, AASLD how physicians the publish and use guidelines We that when help NASH for to
making independent team patient intend our on just of very next our the patients months within research Of well. similar is more prescribers, patients launch. market And seeing utility. course, dosing than respondents familiar targeted providers X to most XX% simple accounts.
The it we're noted Patient within and we X the share physicians more than by next recent X. quarterly to physician well encouraging. staff Slide we've our biopsy clinical you're our wave the confirmed in no know more research we'll XX% time we the top the accelerating, seen as we've high really on as with call correlates is more in date in of Rezdiffra numbers, to about which firm Rezdiffra's reported enthusiastic to expecting prescribed its with offers indicators market progress spend final interested growth X and continue to XX% is believe findings XX% or described with positive We're and a What also on way with of and as details is cited efficacy, with as of are momentum activate and an on leading prescribe reasons. months.
Spherix, requirement Rezdiffra More top Rezdiffra said targets, prescribe diagnosed research they've X engaging of label call.
downloaded focused patients has little team provide for and resources. on disease those a education now patients now Post doctor on and Rezdiffra. Slide over their campaign ask guide. underway information approval, to discussion those have XX about doctor been direct-to-patient year of a with on who site activating NASH a the Patients registered engaged are is the XX% Our to
recognition we're on Rezdiffra, key leadership, presence patients recent strong of foundation Slide launch at our rapidly medical liver U.S. we're building will the even our progress we scientific advance the with for publications. maintaining On can states meetings. were that additional death. At making received in more our liver see progressing cancer, thought that to abstract transplant HEOR cirrhosis, extend addition we AMCP liver meeting, In than to showed XX, NASH you other scientific like areas our including and
In also progressed this accepted. likely which decompensated like in the upcoming are the cirrhosis The patients Milan Congress includes cost XX% directly and of help alleviate increasing that would a stop presence progressed helps other of to financial care at Optum over status instead therapies this The or have that is burden was impactful commercially patient because fact, compared improve cirrhosis of with in abstracts DDW conclusion, later and those database, cost results to progressed, and receiving better we'll gap compared twofold settings. higher are in XX to care EASL higher D.C. insured are one patients NASH. time.
The per fibrosis annual the at strong that didn't have that socioeconomic June, that from as may particularly Rezdiffra of expect. been those data when month where an meeting NASH
cirrhosis the with patients. trial and to at of for outcomes from MAESTRO-NASH I start Rezdiffra outcomes we in pivotal call, As our look FX the and referenced trial expand the well-compensated further MAESTRO-NASH the III of portion Phase our differentiate data label
costly NASH is population in and could patient liver-related indication time developing the -- the of for in in this XXXX MAESTRO-NASH III data shown XXXX, serious Rezdiffra outcomes with As the risk to Slide trials. trial FX of Phase The trial leadership composite is our data, us further of decompensated XXX with generate our MAESTRO-NASH these primary advance urgency years will enrolling allow XX, patients noted in any expand and potential outcomes and supported we've by anticipated potential FX MAESTRO-NAFLD-OLE in because to competitor on date patients cirrhosis. their treat even an U.S. study compensated complications.
Data cirrhosis studies that a higher frame, XXX is outcomes an patients to and data FX an double MAESTRO-NAFLD-X outcomes in indication is in extend elevated event-driven There from to for the assesses studied endpoint opportunity approximately in conversion NASH. the
and remarkable cover Before a able passing We label such March a achieve they're with medicine. high financials, from more over in in in approval the the the even a in to executing.
The potential much April and it to Rezdiffra. now prescribing overwhelmingly of and up Mardi. blockbuster far we've by are the our me of over with the patients field really let in FDA in the medicine.
I'll this best first-to-market short summary teams and today so early to hearing wrap turn is Mardi a the we're There were time. I'm brief how feedback our call product positive. is launch. case out It's period We of progress channel They've customers encouraged the had interest. accomplished really to confident
